Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-10. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
It is synthesized from lathosterol by the enzyme lathosterol oxidase (lathosterol 5-desaturase). This is the next-to-last step of cholesterol biosynthesis. Defective synthesis results in the human inherited disorder lathosterolosis resembling Smith–Lemli–Opitz syndrome. Mice where this gene has been deleted lose the ability to increase vitamin D3 in the blood following UV exposure of the skin. The skin consists of two primary layers: an inner layer, the dermis, comprising largely connective tissue, and an outer, thinner epidermis. The thickness of the epidermis ranges from 0.04 mm to greater than 0.6 mm. The epidermis comprises five strata; from outer to inner, they are the stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum basale. The highest concentrations of 7-dehydrocholesterol are found in the epidermal layer of skin—specifically in the stratum basale and stratum spinosum. The production of pre-vitamin D3 is, therefore, greatest in these two layers.
That evidence bolstered the hypothesis that heavier elements are the product of nucleosynthesis in stars. More recently, such observations provided evidence that elements are formed by neutron capture in the s-process. Since that discovery, there have been many searches in terrestrial materials for natural sources of technetium. In 1962, technetium-99 was isolated and identified in pitchblende from the Belgian Congo in very small quantities (about 0.2 ng/kg), where it originates as a spontaneous fission product of uranium-238. The natural nuclear fission reactor in Oklo contains evidence that significant amounts of technetium-99 were produced and have since decayed into ruthenium-99.
Perhaps the best-known hypothesis involving mercury and autism involves the use of the mercury-based compound thiomersal, a preservative that has been phased out from most childhood vaccinations in developed countries including the US and EU. There is no scientific evidence for a connection between thiomersal and autism, but parental concern about a relationship between thiomersal and vaccines led to decreasing rates of childhood immunizations and increasing likelihood of disease outbreaks in the 1990s. In 1999, the U.S. Public Health Service recommended that thiomersal be removed from childhood vaccines. By 2002, the flu vaccine was the only childhood vaccine using thiomersal. The removal of thiomersal did not decrease autism rates in any country that removed thiomersal from their childhood vaccines. A causal link between thiomersal and autism has been rejected by international scientific and medical professional bodies including the American Medical Association, the American Academy of Pediatrics, the American College of Medical Toxicology, the Canadian Paediatric Society, the U.S. National Academy of Sciences, the Food and Drug Administration, Centers for Disease Control and Prevention, the World Health Organization, the Public Health Agency of Canada, and the European Medicines Agency.
The colony's participation in the Empire Air Training Scheme is described in J F MacDonald's War History of Southern Rhodesia as "undoubtedly Southern Rhodesia's greatest single contribution to the Allied victory", an assertion corroborated by Robert Blake in his 1977 History of Rhodesia. The Rhodesian Air Training Group (RATG) under Air Vice-Marshal Sir C W Meredith eventually operated 11 aerodromes, requiring a huge national effort to build, maintain and staff—at the scheme's peak more than a fifth of the white population was involved. This judicious management of skills and resources allowed the territory to make a much larger contribution to the Allied war effort than if it had simply sent all its manpower into the field. Southern Rhodesia was regarded as an ideal location for air training for a number of reasons. It was far from the hostilities, firmly pro-British and had excellent weather throughout the year. The British Air Ministry resolved to outsource training to the colony amid some urgency in late 1939 after EATS took a long time to get going in Canada. The RATG was the last EATS group to be formed, but the first to start training airmen; it also turned out fully qualified pilots before any of the others, doing so for the first time in November 1940. The programme originally called only for an initial training wing and six schools, but this was expanded to eight flying schools and a school for bomb aimers, navigators and air gunners. There were two air firing and bombing ranges.
== Treatment == Surgery, with as wide a margin of removal as possible, has generally been the most effective and preferred way to attack LMS. If surgical margins are narrow or not clear of tumor, however, or in some situations where tumor cells were left behind, chemotherapy or radiation has been shown to give a clear survival benefit. While LMS tends to be resistant to radiation and chemotherapy, each case is different and results can vary widely. For metastatic (widespread) disease, chemotherapy and targeted therapies are the first choices. Chemotherapy regimens include doxorubicin/ifosfamide and doxorubicin combination/gemcitabine and docetaxel/trabectedin; pazopanib is the targeted therapy used in metastatic leiomyosarcoma as second line and is well tolerated. LMS of uterine origin often responds to hormonal treatments. As of 2020, several clinical trials for uterine LMS are active.
Sources: en.wikipedia.org
=== Nausea and vomiting === Intravenous dexamethasone is effective for the prevention of nausea and vomiting in people who had surgery and whose post-operative pain was treated with long-acting spinal or epidural spinal opioids. The combination of dexamethasone and a 5-HT3 receptor antagonist such as ondansetron is more effective than a 5-HT3 receptor antagonist alone in preventing postoperative nausea and vomiting.
Mukasey (1963), attorney general of the United States; former chief judge of the United States District Court for the Southern District of New York David Saxe (1963), associate justice of the Appellate Division of the New York Supreme Court, First Judicial Department and former judge on the New York Supreme Court Peter Zimroth (1963), assistant U.S. attorney for the Southern District of New York and assistant New York County district attorney, professor at the New York University School of Law Barry Kamins (1965), New York City Criminal Court judge and professor at the Fordham University School of Law and Brooklyn Law School Howard Matz (1965), senior judge of the United States District Court for the Central District of California Flemming L. Norcott Jr. (1965), former associate justice of the Connecticut Supreme Court Joel Klein (1967), assistant attorney general of the United States; chancellor of the New York City Department of Education Anthony C. Moscato (1967), acting inspector general of the Department of Justice and director of the Executive Office for United States Attorneys David M. Becker (1968), two-time general counsel of the U.S. Securities and Exchange Commission Nicholas G. Garaufis (1969), judge of the United States District Court for the Eastern District of New York and former chief counsel of the Federal Aviation Administration Jonathan D.
Sink test is a form of medical laboratory diagnostics healthcare fraud whereby clinical specimens are discarded, via a sink drain, and fabricated results are reported, without the clinical specimen actually being tested. In the United States, the prevalence of sink test laboratories in the 1980s led in part to regulation following the passage of Clinical Laboratory Improvement Amendments in 1988. While this illegal practice still occurs, it is rare within the highly regulated US lab market.
== Contraindications == Contraindications of atenolol include sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt heart failure. There is no basis for use of atenolol in people with heart rate of lower than 50 bpm or systolic blood pressure of less than 100 mm Hg and hence these can be considered contraindications. It is also contraindicated in people with a history of hypersensitivity to atenolol or any of the drug product's other components.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.